Evotec licenses Ncardia’s disease modeling patents

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)

Related tags License Patent Stem cell

Ncardia has entered into a non-exclusive licensing agreement with Evotec through which the drug discovery solutions company will gain access to Ncardia’s stem cell derived cellular disease modeling IP.

Ncardia – which was established in September 2017 following the merger of Pluriomics and Axiogenesis – provides standardized, validated induced pluripotent stem cell (iPSC)​ assays for safety, phenotypic screening, and disease modeling.

The company’s product portfolio encompasses a panel of hiPSC derived cryopreserved cardiomyocytes and neurons. It also delivers the CardioPlate product line of quality controlled ready to use assay plates.

The agreement – financial terms of which were not disclosed – is the second for Ncardia in the past two months. In October, the company announced a license agreement with Roche, Ncardia’s first pharmaceutical partner.

As part of the agreement, Roche has a worldwide license to Ncardia’s disease modeling patents to further discovery and development of novel drug candidates.

The company also completed a €10.5m ($12.42) Series B financing round in November.

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more